AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02360059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
Study NCT02360059 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.
Study NCT02360059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
Study NCT02360059 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
Study NCT02360059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory and Fine-Motor Tests
Description: Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
Study NCT02360059 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sensory and Fine-Motor Tests
Description: Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
Study NCT01741428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention (INT1)
Description: The course Program at the Feiring Heart Clinic will:~Clinical examination and ergospirometric testing, optimizing both treatment and prophylactic medication. Promoting physical Activity, changes in lifestyle, dietary changes/weight reduction, smoking cessation. In the follow-up period the participants will be contacted and report regularly through a web-based secure program (MedAxess)(such as: Activity-, dietary- and smoking habits). Each participant will have their own Mentor, helping keeping up the motivation. They will also meet regularly at the local doctors Office which reports relevant parameters to the Project (such as weight, BP, Lipoproteins, blood glucose/HbA1C)
Study NCT01581073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
Study NCT01581073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
Study NCT01738490 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bone anchored hearing implant
Study NCT04177745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot application
Description: Before PVC was inserted, the researcher applied a hot application to the catheter insertion site (inner surface of the forearm) using a hot pack for one minute.
Study NCT04177745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold application
Description: Before PVC was inserted, the researcher applied a cold application to the catheter insertion site (inner surface of the forearm) using a cold pack for one minute.
Study NCT00768105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Dose titration of oral suspension to a tolerable dose in 2-3 dose steps. Investigational product given twice daily for eight days.
Study NCT00768105 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosing to match AZD1656
Study NCT03598673 — intervention group
Intervention type: DRUG
Intervention: The Efficacy and Tolerability of Nebivolol in Nigerians
Description: To determine the effect of Nevibolol on office blood pressure of Blacks residing in Nigeria
Study NCT04201418 — intervention group
Intervention type: DRUG
Intervention: Patisiran
Description: Patisiran-lipid complex injection, for intravenous use
Study NCT00047554 — intervention group
Intervention type: DRUG
Intervention: Travoprost, 0.004% ophthalmic solution
Study NCT01544816 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Snack Product
Description: control food product
Study NCT01544816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snack Product
Description: Experimental food product containing ingredient 1
Study NCT01544816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snack Product
Description: Experimental food product containing ingredient 2
Study NCT03173196 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive Multispectral Sonography
Description: We measure both groups wirh the non-invasive multispectral sonography for 3 and for 30 minutes.
Study NCT03937375 — intervention group
Intervention type: BEHAVIORAL
Intervention: High PEEP
Description: Use of high levels of PEEP combined with recruitment maneuvers and low tidal volume ventilation during general anesthesia
Study NCT03937375 — intervention group
Intervention type: BEHAVIORAL
Intervention: Low PEEP
Description: Use of low levels of PEEP without recruitment maneuvers and low tidal volume ventilation during general anesthesia
Study NCT01111500 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Donjoy ER brace
Description: Patients will wear an external rotation brace, the Donjoy ER brace, during treatment.
Study NCT01111500 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thoraco brachial brace
Description: Patients will wear an internal rotation brace, a thoraco brachial brace, during treatment.
Study NCT04153409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAT8881
Description: Two 30 mg capsules of LAT8881
Study NCT04153409 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules of placebo
Study NCT01506245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based behavioral therapy
Description: The intervention consist of a 6-month family-based behavioural therapy either in group (1 session/week, with a dietician and a psychologist) or in individual setting (with a paediatrician or a dietician in alternance 1x/month). Both therapies include exercise training twice per week (60 minutes each). Parents, or at at least the mother, must participate to the behavioral treatment.
Study NCT03901248 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Observational study
Study NCT00840970 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-coated Intranasal Splint
Description: placement of non-coated intranasal splint following FESS
Study NCT00840970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinexus Intranasal Splint
Description: placement of Sinexus Intranasal Splint placed following FESS
Study NCT02998294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Volume Monitor(RVM)
Description: The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
Study NCT02998294 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial respirator
Description: The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
Study NCT01701375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0332991
Description: • PD 0332991 will be given orally days 1,2,3
Study NCT04620317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: 10 billion (B) colony forming unit (CFU) of Lactobacillus plantarum LP01, Bifidobacterium lactis BB12, and inulin oligofructose
Study NCT04620317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active ingredients - Maltodextrins
Study NCT00504829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCP-AtorFen
Description: 40mg atorvastatin combined with 100mg fenofibrate in a tablet for once daily treatment of dyslipidemia and mixed dyslipidemia
Study NCT00504829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: dyslipidemia and mixed dyslipidemia
Study NCT00504829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate
Description: dyslipidemia and mixed dyslipidemia
Study NCT03465540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 397
Description: AMG 397 will be administered orally once or twice weekly as part of a 28-day treatment cycle.
Study NCT03465540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered intravenously (IV) or orally on Days 1, 8, 15, and 22 of each 28-day cycle.
Study NCT03465540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine will be administered intravenously (IV) or subcutaneously (SC) daily for the first 7 days of a 28-day cycle.
Study NCT01771003 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CellAegis' autoRIC™ Device
Description: Patients in the active group will have the autoRIC device (like a blood pressure cuff) inflated and deflated to a pressure of 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles
Study NCT01771003 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: CellAegis' autoRIC™ Device
Description: Patients in the active group will have the autoRIC device (like a blood pressure cuff) inflated and deflated to a pressure of 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles
Study NCT01850160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GROUP A: Valsartan plus Chlorthalidone
Description: Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
Study NCT01850160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GROUP B: Valsartan
Description: GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
Study NCT01850160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GROUP C: Chlorthalidone
Description: GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
Study NCT03103867 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM augmented pump with PLGS ,
Description: 5 weeks treatment CGM augmented pump with PLGS compared with 5 weeks treatment with insulin pump with CGM , without integration
Study NCT03103867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump with CGM
Description: 5 weeks treatment continuous subcutaneous insulin infusion pump with CGM without data integration,
Study NCT01490060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: 150 mg administered intravenously, delivered in either single dose or two doses, on Day 1 for single dose and on Days 1 and 4 for two doses, varying between Cycle 1 or Cycle 2 depending upon randomization to arm.
Study NCT01490060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous push (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5)
Study NCT01490060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5HT3 receptor antagonist
Description: 5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy
Study NCT01490060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide-based chemotherapy (AI)
Description: Doxorubicin + Mesna + + Ifosfamide + Vincristine, chemotherapy cycles repeated every 3-4 weeks for up to 6 cycles. Chemotherapy drugs listed separately, individual dosages, etc.
Study NCT01490060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m\^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m\^2) as part of AI Chemotherapy.
Study NCT01490060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Prior to ifosfamide (Day 1) - 500 mg/m\^2 (20% of ifosfamide dose) given simultaneously with ifosfamide and then daily continuous infusion (Days 1-4 completing infusion on day 4) - 1,500 mg/m\^2/day (60% of daily ifosfamide dose) for a total of 6 gm/m\^2. The mesna infusion complete 24 hours after last dose of ifosfamide.
Study NCT01490060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: 2.5 g/m\^2 IV bolus over 3 hours on days 1, 2, 3, 4 (total dose: 10 g/m\^2).
Study NCT01490060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.
Study NCT03789539 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LD Universal Influenza Vaccine Uniflu
Description: low dose Universal Influenza Vaccine Uniflu
Study NCT03789539 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HD Universal Influenza Vaccine Uniflu
Description: High dose Universal Influenza Vaccine Uniflu
Study NCT03789539 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo saline
Study NCT01877421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg KSL-W
Study NCT01877421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg KSL-W
Study NCT01877421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg KSL-W
Study NCT01877421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg KSL-W
Study NCT01877421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg KSL-W
Study NCT01877421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg KSL-W
Study NCT01877421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg KSL-W
Study NCT01877421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg KSL-W
Study NCT01877421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg KSL-W
Study NCT01877421 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.
Study NCT04592757 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual mirror therapy via VR headset
Description: Participants will perform Activities of Daily Living (ADL) in a virtual environment through a VR headset. The application is based on mirror therapy. Participants will execute certain arm movements with their non-affected arm, while seeing their affected arm perform said movement in the virtual environment.
Study NCT04289649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-924 LD
Description: Pitavastatin 2 mg / Ezetimibe 10 mg tables
Study NCT04289649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-924 HD
Description: Pitavastatin 4 mg / Ezetimibe 10 mg tables
Study NCT04289649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: K-924 LD Placebo
Description: Pitavastain 2 mg
Study NCT04289649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: K-924 HD Placebo
Description: Pitavastain 4 mg
Study NCT04812353 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up of Io-Fix type fixation
Description: Follow-up of patients who underwent a foot- or ankle reconstruction surgery using the Io-Fix system
Study NCT00984269 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tourniquet Use
Description: Patients undergoing hand/wrist surgery with or without a tourniquet
Study NCT00383435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) combination
Description: MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
Study NCT00383435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) combination
Description: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
Study NCT00383435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate MDI (MF MDI)
Description: MF 400 mcg via metered dose inhaler twice daily for 52 weeks
Study NCT00383435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol MDI
Description: Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
Study NCT00383435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo MDI twice a day for 26 weeks
Study NCT01691300 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACT PET/CT
Description: Old tracer but new indication
Study NCT00902200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-12286
Description: See arms
Study NCT00902200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AR-12286 vehicle
Description: See arms
Study NCT02942160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Study NCT02660944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSLV-132
Description: RNase-Fc fusion protein
Study NCT02660944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo
Study NCT03284268 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VCN-01
Description: VCN-01 intravitreal injection
Study NCT03649906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optimized Localization Technique
Description: The small pulmonary nodules of the subjects will be located using an optimized pre-loaded microcoil puncture locating method.
Study NCT01635127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: 150mg s.c.
Study NCT03319927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPM educational workshop and consultation
Description: The interventions include a baseline assessment conducted by a research assistant and objective measures of pesticide exposure (center dust samples, children's silicone wristbands), review of assessment by the nurse child care health consultant, goal setting with the director, educational workshop, 7 monthly consultation visits, and post-intervention review of goals and post-assessment findings (conducted by research assistant and objective measures of pesticide exposure).
Study NCT03319927 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IPM educational workshop and consultation
Description: The interventions include a baseline assessment conducted by a research assistant and objective measures of pesticide exposure (center dust samples, children's silicone wristbands), review of assessment by the nurse child care health consultant, goal setting with the director, educational workshop, 7 monthly consultation visits, and post-intervention review of goals and post-assessment findings (conducted by research assistant and objective measures of pesticide exposure).
Study NCT00548782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paleolithic diet
Description: diet
Study NCT00548782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ADA ( American Diabetes Association) recommended diet
Description: diet
Study NCT02341248 — intervention group
Intervention type: OTHER
Intervention: Exclusive Enteral Nutrition (EEN)
Description: 8 week standard course of treatment with EEN
Study NCT04242316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Patients performed customized bimanual upper limb exercises with graded level of difficulty based on the patient's individual levels of upper limb functioning according to the 7 levels of the FTHUE and each level consisted of 5 standardized table-top tasks. The patients practiced the movements with the unaffected hand (including the shoulder, elbow, wrist, and hand). While watching the reflection of the unaffected hand in the mirror, the patient was then asked to moving the affected hand at the same time to synchronize the movement with the reflection of the unaffected hand. If the patient was unable to move the hand, a therapist would passively assist the movement of the affected hand so as to synchronize it with the reflection of the unaffected hand.